Lin Shen

18.0k total citations · 7 hit papers
279 papers, 7.1k citations indexed

About

Lin Shen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Lin Shen has authored 279 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 148 papers in Oncology, 122 papers in Pulmonary and Respiratory Medicine and 68 papers in Surgery. Recurrent topics in Lin Shen's work include Gastric Cancer Management and Outcomes (90 papers), Cancer Immunotherapy and Biomarkers (61 papers) and Esophageal Cancer Research and Treatment (40 papers). Lin Shen is often cited by papers focused on Gastric Cancer Management and Outcomes (90 papers), Cancer Immunotherapy and Biomarkers (61 papers) and Esophageal Cancer Research and Treatment (40 papers). Lin Shen collaborates with scholars based in China, United States and Ethiopia. Lin Shen's co-authors include Jingkun Xu, Hyunwoo Yuk, Xuanhe Zhao, Kai Qu, Jianhong Luo, Baoyang Lu, Jifang Gong, Zhi Peng, Jing Gao and Cheng Zhang and has published in prestigious journals such as Nature, The Lancet and Nature Medicine.

In The Last Decade

Lin Shen

262 papers receiving 7.0k citations

Hit Papers

3D printing of conducting polymers 2013 2026 2017 2021 2020 2021 2013 2023 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. 3D printing of conducting polymers
    2020 813 citations Lin Shen et al. profile →
  2. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
    2021 449 citations Lin Shen, Kohei Shitara et al. profile →
  3. Management of gastric cancer in Asia: resource-stratified guidelines
    2013 384 citations Lin Shen et al. profile →
  4. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
    2023 213 citations Lin Shen, Kohei Shitara et al. profile →
  5. The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth
    2021 201 citations Zhenghang Wang, Lin Shen et al. profile →
  6. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial
    2022 101 citations Lin Shen et al. profile →
  7. Claudin 18.2 as a novel therapeutic target
    2024 73 citations Changsong Qi, Lin Shen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lin Shen China 38 2.9k 2.4k 1.7k 1.5k 1.0k 279 7.1k
Yutaka Takahashi Japan 42 2.0k 0.7× 1.6k 0.7× 3.1k 1.8× 1.1k 0.7× 1.2k 1.2× 305 8.1k
Zhenning Wang China 54 3.4k 1.2× 2.8k 1.2× 4.3k 2.5× 2.6k 1.7× 3.1k 3.0× 397 10.5k
Song Cheol Kim South Korea 39 3.7k 1.3× 1.7k 0.7× 810 0.5× 2.6k 1.7× 667 0.7× 298 5.9k
Seung‐Mo Hong South Korea 55 6.7k 2.3× 1.9k 0.8× 3.5k 2.0× 3.6k 2.3× 2.5k 2.4× 379 11.1k
Hideki Ueno Japan 59 8.5k 2.9× 3.6k 1.5× 1.5k 0.8× 4.3k 2.8× 1.6k 1.6× 438 12.4k
Caroline S. Verbeke Norway 39 3.2k 1.1× 969 0.4× 1.2k 0.7× 1.8k 1.2× 710 0.7× 136 6.3k
Sunil Singhal United States 59 3.0k 1.0× 3.8k 1.6× 2.2k 1.3× 1.9k 1.2× 893 0.9× 336 12.0k
Xiujun Cai China 46 1.4k 0.5× 1.3k 0.5× 3.2k 1.8× 1.2k 0.8× 2.0k 1.9× 241 7.0k
Jeong Hyeon Lee South Korea 42 1.4k 0.5× 794 0.3× 1.8k 1.0× 1.1k 0.7× 683 0.7× 283 6.8k
Ziyu Li China 35 1.0k 0.4× 1.7k 0.7× 1.5k 0.8× 1.1k 0.7× 629 0.6× 279 4.6k

Countries citing papers authored by Lin Shen

Since Specialization
Citations

This map shows the geographic impact of Lin Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lin Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lin Shen more than expected).

Fields of papers citing papers by Lin Shen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lin Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lin Shen. The network helps show where Lin Shen may publish in the future.

Co-authorship network of co-authors of Lin Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Lin Shen. A scholar is included among the top collaborators of Lin Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lin Shen. Lin Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Qi, Changsong, Chang Liu, Xiaofei Wei, et al.. (2024). Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells. Journal for ImmunoTherapy of Cancer. 12(10). e009960–e009960. 5 indexed citations
3.
Jia, Keren, Chen Yang, Yi Xie, et al.. (2024). Helicobacter pylori and immunotherapy for gastrointestinal cancer. The Innovation. 5(2). 100561–100561. 33 indexed citations
4.
5.
6.
Qiu, Yue, Zhen Tian, Lin Shen, et al.. (2024). The METTL3-m6A-YTHDC1-AMIGO2 axis contributes to cell proliferation and migration in esophageal squamous cell carcinoma. Gene. 908. 148281–148281. 4 indexed citations
7.
Shen, Lin, Caicun Zhou, Yinghua Ji, et al.. (2024). Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3012–3012. 9 indexed citations
8.
Shen, Lin, Kohei Shitara, Jen‐Shi Chen, et al.. (2024). GEMINI-Gastric: A phase 2 study of novel treatment combinations in patients with locally advanced unresectable or metastatic gastric cancers.. Journal of Clinical Oncology. 42(16_suppl). TPS4182–TPS4182. 1 indexed citations
9.
Shen, Lin, et al.. (2023). Altered gut microbiota profile in patients with perimenopausal panic disorder. Frontiers in Psychiatry. 14. 1139992–1139992. 4 indexed citations
10.
Gao, Jing, Haiyan Liao, Fang Yang, et al.. (2023). Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges. BMC Cancer. 23(1). 1205–1205. 13 indexed citations
11.
Xie, Tong, Zhening Zhang, Zhi Peng, & Lin Shen. (2023). Next stage of collaboration in East Asia gastric cancer treatment. Chinese Clinical Oncology. 12(4). 39–39. 2 indexed citations
12.
13.
Shen, Lin, et al.. (2023). Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer. Journal of the Korean Gastric Cancer Association. 23(1). 182–182. 1 indexed citations
14.
Drilon, Alexander, Lin Shen, François Doz, et al.. (2023). 668P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer. Annals of Oncology. 34. S470–S470. 2 indexed citations
15.
Wei, Qing, Ting Xu, Xiaotian Zhang, et al.. (2021). A multicenter study assessing the prevalence of germline genetic alterations in Chinese gastric-cancer patients. Gastroenterology report. 9(4). 339–349. 5 indexed citations
16.
Peng, Zhi, Jia Wei, Wang Feng, et al.. (2021). Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research. 27(11). 3069–3078. 75 indexed citations
17.
Huang, Hsuan‐Ying, Xiaojie Fang, Zhenchang Wang, et al.. (2020). A New Immunological Prognostic Model Based on Immunohistochemistry for Extranodal Natural Killer/T-Cell Lymphoma Patients After Non-Anthracycline-Based Chemotherapy. SHILAP Revista de lepidopterología. 1 indexed citations
18.
Ge, Shenglin, Lin Shen, Li Zhang, & Ming Zeng. (2020). The Association of Red Blood Cell Distribution Width to Platelet Count Ratio and 28-Day Mortality of Patients with Sepsis: A Retrospective Cohort Study. SHILAP Revista de lepidopterología. 2 indexed citations
19.
Xu, Lifeng, et al.. (2019). Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway. SHILAP Revista de lepidopterología. 2 indexed citations
20.
Gao, Jianguo, et al.. (2014). Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls. SHILAP Revista de lepidopterología. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yutaka Takahashi Breakdown of academic impact, for papers by Zhenning Wang Breakdown of academic impact, for papers by Song Cheol Kim Breakdown of academic impact, for papers by Seung‐Mo Hong Breakdown of academic impact, for papers by Hideki Ueno Breakdown of academic impact, for papers by Caroline S. Verbeke Breakdown of academic impact, for papers by Sunil Singhal Breakdown of academic impact, for papers by Xiujun Cai Breakdown of academic impact, for papers by Jeong Hyeon Lee Breakdown of academic impact, for papers by Ziyu Li
Rankless by CCL
2026